<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Eurand N.v.</title>
	<atom:link href="http://www.stockbloghub.com/tag/eurand-n-v/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(LLY) Eli Lilly Boosts Pipeline</title>
		<link>http://www.stockbloghub.com/2010/07/07/lly-eli-lilly-boosts-pipeline/42828</link>
		<comments>http://www.stockbloghub.com/2010/07/07/lly-eli-lilly-boosts-pipeline/42828#comments</comments>
		<pubDate>Wed, 07 Jul 2010 19:02:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Eurand N.v.]]></category>
		<category><![CDATA[EURX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=42828</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced that it intends to acquire privately held biotech company Alnara Pharmaceuticals Inc. Alnara specializes in the development of protein therapeutics for the treatment of metabolic diseases. The financial terms of the deal were not disclosed. With this acquisition, Eli Lilly is looking to enter the enzyme replacement therapy market, which is still significantly unmet. Eli Lilly will gain access to Alnara’s lead candidate, liprotamase, which is currently under US Food and Drug Administration (FDA) review for the treatment of exocrine pancreatic insufficiency (EPI). Alnara is also developing a pediatric formulation of liprotamase. In addition to being observed in chronic pancreatitis and pancreatectomy cases, exocrine pancreatic insufficiency is often observed in patients suffering from cystic fibrosis which is estimated to affect about 30,000 children ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/07/lly-eli-lilly-boosts-pipeline/42828/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EURX) FDA Approves Eurand Drug</title>
		<link>http://www.stockbloghub.com/2009/08/31/eurx-pep-fda-approves-eurand-drug/13960</link>
		<comments>http://www.stockbloghub.com/2009/08/31/eurx-pep-fda-approves-eurand-drug/13960#comments</comments>
		<pubDate>Mon, 31 Aug 2009 20:49:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eurand N.v.]]></category>
		<category><![CDATA[EURX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13960</guid>
		<description><![CDATA[On Friday, the U.S. Food and Drug Administration (FDA) approved Eurand N.V.&#8216;s (EURX) New Drug Application for its pancreatic enzyme product {PEP} Zenpep. The product targets a condition where insufficient secretion of enzymes by the pancreas hampers digestion of food. This phenomenon, known as exocrine pancreatic insufficiency {EPI}, causes malnutrition, impaired growth in children, compromised immune response and shortened life expectancy. EPI is very common in cystic fibrosis patients. Cystic fibrosis causes life-threatening lung infections and serious digestive complications. Zenpep, which improves digestion and absorption by replacing the missing enzymes, is the only FDA-approved PEP to be tested in adults and children below 12 years of age. The approval of Zenpep is a major milestone for EPI patients. The drug would enable doctors to fine tune treatment regimens to achieve ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/31/eurx-pep-fda-approves-eurand-drug/13960/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

